Immunovant, Inc.

IMVT

$1.87B

Small Cap

NASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaNEW YORK362 employees

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Mar 15, 2026

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

2 upcoming, 2 past

⭐Phase 3Next

Batoclimab Phase 3 Results Expected

March 2026~Batoclimab100

Primary completion for Batoclimab trial (NCT05524571) in Thyroid Eye Disease

Source

⭐Phase 3

Batoclimab Phase 3 Results Expected

August 2026~Batoclimab180

Primary completion for Batoclimab trial (NCT05517447) in Thyroid Eye Disease

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

IMVT-1402

Phase 3

Chronic Inflammatory Demyelinating Polyneuropathy

Batoclimab

Phase 3

Thyroid Eye Disease

Batoclimab 680 mg SC weekly

Phase 3

Generalized Myasthenia Gravis

Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly

Phase 2

Chronic Inflammatory Demyelinating Polyneuropathy

RVT-1401

Phase 2

Myasthenia Gravis

IMVT-1401 (batoclimab)

Phase 2

Graves Disease

Drug Name	Phase	Indication	Designations
IMVT-1402	Phase 3	Chronic Inflammatory Demyelinating Polyneuropathy	-
Batoclimab	Phase 3	Thyroid Eye Disease	-
Batoclimab 680 mg SC weekly	Phase 3	Generalized Myasthenia Gravis	-
Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly	Phase 2	Chronic Inflammatory Demyelinating Polyneuropathy	-
RVT-1401	Phase 2	Myasthenia Gravis	-
IMVT-1401 (batoclimab)	Phase 2	Graves Disease	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

IMVT News